<strong>Combination treatment with </strong><strong>an</strong><strong> AURKA inhibitor and anti-B7-H3 mAbs enhances antitumor efficacy through the EGFR/B7-H3 pathway and CD8+ T-cell infiltration in glioblastoma</strong>. The gene discussed is CD8A; the disease is glioblastoma.